This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.
Evidence of measurement bias undermines past claims about autistic children’s lower well-being.
Studies of behavioral treatments for autism are complex and can easily be misunderstood. Here we provide some guidance.
Male rats prenatally exposed to a maternal immune response have atypical responses to other rats in distress, according to a new study.
Discussion on social media revolved around a meta-analysis of suicidality in autism, a method to purify neural stem and progenitor cells, and autism-linked genes in zebrafish.
Here is a roundup of news and research for the week of 20 March.
People whose brains look like those of people who carry autism-linked copy number variants also share markers of heart health.
About 1 in 36 children in the United States has autism, up almost 20 percent from the previous estimate, reflecting improved identification, particularly among girls and Black, Hispanic and Asian or Pacific Islander children.
Cannabidiol (CBD) blocks the action of a molecule that drives an overexcitability feedback loop in a rodent model of epilepsy.
The approach improves the function of SYNGAP1-deficient neurons in vitro, but whether it will work in people remains unclear.